executive_orderEvent Saturday, April 18, 2026Analyzed

Executive Order: Accelerating Medical Treatments for Serious Mental Illness

Bullish

Summary

This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.

See which stocks are affected

Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.

Already have an account? Log in

Key Takeaways

  • 1.FDA Commissioner to provide National Priority Vouchers to appropriate psychedelic drugs with Breakthrough Therapy designation.
  • 2.FDA and DEA to establish a pathway for eligible patients to access psychedelic drugs under the Right to Try Act, including Schedule I handling authorizations.
  • 3.HHS to allocate at least $50 million to support state governments advancing psychedelic drug programs.
  • 4.HHS, FDA, and VA to collaborate with the private sector to increase clinical trial participation and data sharing for psychedelic drugs.
  • 5.Attorney General to initiate and complete timely review for rescheduling of Schedule I substances that successfully complete Phase 3 clinical trials for serious mental health disorders.

Market Implications

This action is expected to significantly accelerate the development, approval, and patient access to psychedelic-based therapies for mental health, creating a more favorable regulatory and funding environment for companies in this nascent industry.

Full Analysis

This action is expected to significantly accelerate the development, approval, and patient access to psychedelic-based therapies for mental health, creating a more favorable regulatory and funding environment for companies in this nascent industry.

Related Presidential Actions

Executive orders & memoranda affecting the same sectors or companies

Exec OrderJun 25, 2026

Advancing Regenerative Agriculture and Strengthening American Farm Resilience

This executive order directs the EPA, USDA, and HHS to prioritize registration of alternative pesticides, expedite cumulative exposure research, and maximize funding for a regenerative agriculture pilot program, while creating public-private partnerships to expand adoption of conservation farming practices. The order specifically instructs the EPA Administrator to speed up registration actions for substances that can replace older active ingredients, and requires HHS to issue a grand prize challenge for cumulative chemical exposure evaluation technologies.

Exec OrderJun 3, 2026

Implementing Schedule Policy/Career in the Excepted Service

This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.

Exec OrderMay 29, 2026

Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries

This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.

Free — no credit card

Get the next market-moving signal before the news does

HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.

Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.

Free forever plan · No credit card · Unsubscribe in one click

Want the live terminal too? Create a free account →